Type Size
    ASBMR 2011 Annual Meeting

    Co-morbid Medical Conditions Associated with Prevalent Hypoparathyroidism: A Population-based Study

     Metabolic Bone Disease and Disorders of Mineral Metabolism
     Calciotropic and Phosphotropic Hormones and Mineral Metabolism

    Poster Sessions, Presentation Number: SA0170
    Session: Poster Session I & Poster Tours*
    Saturday, September 17, 2011 11:00 AM - 1:00 PM, San Diego Convention Center, Hall GH

    * , UNITED STATES, Cynthia Leibson, Mayo Clinic, Jane Emerson, Mayo Clinic, Jeanine Ransom, Mayo Clinic, , BE

    Hypoparathyroidism (HypoPARA) is a rare condition with widespread consequences, ranging from asymptomatic presentation to fatal hypocalcemia. Population estimates of prevalence of HypoPARA across the full range of disease and associated patient characteristics are lacking. Using unique longitudinal, population-based Rochester Epidemiology Project (REP) medical records linkage resources, we 1) identified all persons residing in Olmsted County, MN, in 2009 with any diagnosis of HypoPARA assigned by a REP provider since 1945, 2) reviewed detailed medical records to confirm diagnosis of HypoPARA and assign etiology, 3) assigned 2 age- and sex-matched controls per confirmed case, and 4) obtained all medical diagnoses from 2006 through 2008 to compare cases with controls for percent with any diagnosis in each chapter and subchapter of the International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM). There were 54 confirmed cases (prevalence=37/100,000; 71% female; mean age 58±20 years); etiology=78% post-surgical, 9% secondary, 7% familial, 6% idiopathic. Cases were more likely than controls (p<0.05) to have ≥1 diagnosis within 7 of 17 chapters and 15 subchapters. Details on specific chapter and subchapter differences are provided in the table. These population-based data on confirmed HypoPARA prevalence and case characteristics reveal that, compared to unaffected peers, persons with HypoPARA exhibit a substantial burden of comorbid disease across multiple dimensions.

    Disclosures: H. Lagast, NPS Pharmaceuticals, Inc.: Employment (full or part-time). B. Clarke, NPS Pharmaceuticals, Inc.: Research Grants.

    * Presenting Authors(s): , UNITED STATES